1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin; 68: 394-424. 2018.
2.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A.
Colorectal cancer statistics, 2017. CA Cancer J Clin; 67: 177-93. 2017.
Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science; 331:
1559-64. 2011.
Paduch R. The role of lymphangiogenesis and angiogenesis in tumor metastasis.
Cell Oncol (Dordr); 39: 397-410. 2016.
Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d
English Edition [Secondary Publication]. J Anus Rectum Colon; 3: 175-95. 2019.
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta
K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K,
Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H,
Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano
K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H,
Matsuda K, Kotake K, Sugihara K. Japanese Society for Cancer of the Colon and
Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin
Oncol; 25: 1-42. 2020.
Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers
of tumour metastasis. Nat Rev Cancer; 14: 430-9. 2014.
Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer; 11:
393-410. 2011.
Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science; 352: 175-80.
2016.
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM.
Hypoxia promotes invasive growth by transcriptional activation of the met
protooncogene. Cancer Cell; 3: 347-61. 2003.
Schito L. Hypoxia-Dependent Angiogenesis and Lymphangiogenesis in Cancer.
Adv Exp Med Biol; 1136: 71-85. 2019.
Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein
synthesis binds to the human erythropoietin gene enhancer at a site required for
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
62
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
transcriptional activation. Mol Cell Biol; 12: 5447-54. 1992.
Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE; 2007: cm8.
2007.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer; 3: 721-32.
2003.
Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell; 166: 21-45. 2016.
Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev
Pathol; 13: 395-412. 2018.
Williams ED, Gao D, Redfern A, Thompson EW. Controversies around epithelialmesenchymal plasticity in cancer metastasis. Nat Rev Cancer; 19: 716-32. 2019.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions
in development and disease. Cell; 139: 871-90. 2009.
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal
transition. Nat Rev Mol Cell Biol; 15: 178-96. 2014.
Pérez-Pomares JM, Muñoz-Chápuli R. Epithelial-mesenchymal transitions: a
mesodermal cell strategy for evolutive innovation in Metazoans. Anat Rec; 268:
343-51. 2002.
Huber MA, Kraut N, Beug H. Molecular requirements for epithelialmesenchymal transition during tumor progression. Curr Opin Cell Biol; 17: 54858. 2005.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev
Cancer; 2: 442-54. 2002.
Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer
progression. Cancer Biol Ther; 11: 714-23. 2011.
Tam SY, Wu VWC, Law HKW. Hypoxia-Induced Epithelial-Mesenchymal
Transition in Cancers: HIF-1α and Beyond. Front Oncol; 10: 486. 2020.
Hongo K, Tsuno NH, Kawai K, Sasaki K, Kaneko M, Hiyoshi M, Murono K, Tada
N, Nirei T, Sunami E, Takahashi K, Nagawa H, Kitayama J, Watanabe T. Hypoxia
enhances colon cancer migration and invasion through promotion of epithelialmesenchymal transition. J Surg Res; 182: 75-84. 2013.
Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133/CD133/Prominin-1. Int J
Biochem Cell Biol; 37: 715-9. 2005.
Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M,
Nakagawara A, Kamijo T. CD133 suppresses neuroblastoma cell differentiation
via signal pathway modification. Oncogene; 30: 97-105. 2011.
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ,
63
Heeschen C. Distinct populations of cancer stem cells determine tumor growth
and metastatic activity in human pancreatic cancer. Cell Stem Cell; 1: 313-23.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
2007.
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco
L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ; 15: 504-14. 2008.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De
Maria R. Identification and expansion of human colon-cancer-initiating cells.
Nature; 445: 111-5. 2007.
O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable
of initiating tumour growth in immunodeficient mice. Nature; 445: 106-10. 2007.
Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of
the cancer stem cell: current controversies and new insights. Nat Rev Cancer; 5:
899-904. 2005.
Hongo K, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K,
Kaneko M, Hiyoshi M, Sunami E, Kitayama J, Takahashi K, Nagawa H. CD133(-)
cells, derived from a single human colon cancer cell line, are more resistant to 5fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling. J
Surg Res; 175: 278-88. 2012.
Kishikawa J, Kazama S, Oba K, Hasegawa K, Anzai H, Harada Y, Abe H,
Matsusaka K, Hongo K, Oba M, Yasuda K, Otani K, Nishikawa T, Tanaka T,
Tanaka J, Kiyomatsu T, Hata K, Kawai K, Nozawa H, Yamaguchi H, Ishihara S,
Sunami E, Ushiku T, Kitayama J, Fukayama M, Kokudo N, Watanabe T. CD133
Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer
with Synchronous Liver Metastasis. Ann Surg Oncol; 23: 1916-23. 2016.
Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, McDonald PJ, Talbot IC,
Glynne-Jones R, Northover JM, Guenther T. Hypoxia-inducible factor-1alpha and
-2alpha are expressed in most rectal cancers but only hypoxia-inducible factor1alpha is associated with prognosis. Br J Cancer; 100: 1666-73. 2009.
Zhang Q, Han Z, Zhu Y, Chen J, Li W. Role of hypoxia inducible factor-1 in cancer
stem cells (Review). Mol Med Rep; 232021.
Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D,
Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K. mTOR signal and hypoxiainducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res;
69: 7160-4. 2009.
Hashimoto O, Shimizu K, Semba S, Chiba S, Ku Y, Yokozaki H, Hori Y. Hypoxia
64
induces tumor aggressiveness and the expansion of CD133-positive cells in a
hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
Pathobiology; 78: 181-92. 2011.
Maeda K, Ding Q, Yoshimitsu M, Kuwahata T, Miyazaki Y, Tsukasa K, Hayashi
T, Shinchi H, Natsugoe S, Takao S. CD133 Modulate HIF-1α Expression under
Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells. Int J Mol Sci;
172016.
Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF. CD133/Src axis
mediates tumor initiating property and epithelial-mesenchymal transition of head
and neck cancer. PLoS One; 6: e28053. 2011.
Li W, Cho MY, Lee S, Jang M, Park J, Park R. CRISPR-Cas9 mediated CD133
knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal
transition. PLoS One; 14: e0220860. 2019.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin
Invest; 119: 1420-8. 2009.
Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J
Clin Invest; 119: 1429-37. 2009.
Banyard J, Bielenberg DR. The role of EMT and MET in cancer dissemination.
Connect Tissue Res; 56: 403-13. 2015.
Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi
CY. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal
Transition: Signaling, Therapeutic Implications, and Challenges. Cells; 82019.
Vu T, Datta PK. Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis.
Cancers (Basel); 92017.
Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE,
Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines.
Oncogenesis; 2: e71. 2013.
You S, Zhou J, Chen S, Zhou P, Lv J, Han X, Sun Y. PTCH1, a receptor of
Hedgehog signaling pathway, is correlated with metastatic potential of colorectal
cancer. Ups J Med Sci; 115: 169-75. 2010.
Okuno T, Kawai K, Hata K, Murono K, Emoto S, Kaneko M, Sasaki K, Nishikawa
T, Tanaka T, Nozawa H. SN-38 Acts as a Radiosensitizer for Colorectal Cancer
by Inhibiting the Radiation-induced Up-regulation of HIF-1α. Anticancer Res; 38:
3323-31. 2018.
Valenta T, Hausmann G, Basler K. The many faces and functions of β-catenin.
Embo j; 31: 2714-36. 2012.
65
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
Iida Y, N HT, Kishikawa J, Kaneko K, Murono K, Kawai K, Ikeda T, Ishihara S,
Yamaguchi H, Sunami E, Kitayama J, Yatomi Y, Watanabe T.
Lysophosphatidylserine stimulates chemotactic migration of colorectal cancer
cells through GPR34 and PI3K/Akt pathway. Anticancer Res; 34: 5465-72. 2014.
Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell; 129:
465-72. 2007.
Vadde R, Vemula S, Jinka R, Merchant N, Bramhachari PV, Nagaraju GP. Role of
hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy
of colorectal cancer. Crit Rev Oncol Hematol; 113: 22-27. 2017.
Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh
J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM. Hypoxia promotes
expansion of the CD133-positive glioma stem cells through activation of HIF1alpha. Oncogene; 28: 3949-59. 2009.
Santoyo-Ramos P, Likhatcheva M, García-Zepeda EA, Castañeda-Patlán MC,
Robles-Flores M. Hypoxia-inducible factors modulate the stemness and
malignancy of colon cancer cells by playing opposite roles in canonical Wnt
signaling. PLoS One; 9: e112580. 2014.
Archbold HC, Yang YX, Chen L, Cadigan KM. How do they do Wnt they do?:
regulation of transcription by the Wnt/β-catenin pathway. Acta Physiol (Oxf); 204:
74-109. 2012.
Ding Q, Miyazaki Y, Tsukasa K, Matsubara S, Yoshimitsu M, Takao S. CD133
facilitates epithelial-mesenchymal transition through interaction with the ERK
pathway in pancreatic cancer metastasis. Mol Cancer; 13: 15. 2014.
Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents
beta-catenin
nuclear
localization
and
beta-catenin/LEF-1-mediated
transactivation. J Cell Sci; 112 ( Pt 8): 1237-45. 1999.
Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in
malignant progression of cancer. Cancer Metastasis Rev; 28: 151-66. 2009.
Bukholm IK, Nesland JM, Børresen-Dale AL. Re-expression of E-cadherin,
alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue
from breast cancer patients [seecomments]. J Pathol; 190: 15-9. 2000.
Manzo G. Similarities Between Embryo Development and Cancer Process
Suggest New Strategies for Research and Therapy of Tumors: A New Point of
View. Front Cell Dev Biol; 7: 20. 2019.
Giancotti FG, Ruoslahti E. Integrin signaling. Science; 285: 1028-32. 1999.
Cooper J, Giancotti FG. Integrin Signaling in Cancer: Mechanotransduction,
66
Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell; 35: 34767. 2019.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
Cheah M, Andrews MR. Integrin Activation: Implications for Axon Regeneration.
Cells; 72018.
Ata R, Antonescu CN. Integrins and Cell Metabolism: An Intimate Relationship
Impacting Cancer. Int J Mol Sci; 182017.
Lokmic Z, Musyoka J, Hewitson TD, Darby IA. Hypoxia and hypoxia signaling
in tissue repair and fibrosis. Int Rev Cell Mol Biol; 296: 139-85. 2012.
Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, Chen J,
Kobayashi M, Hosokawa M, Taniguchi A, Kojima T, Ishida N, Kawakita M,
Yamamoto H, Takematsu H, Suzuki A, Kozutsumi Y, Kannagi R. Hypoxia induces
adhesion molecules on cancer cells: A missing link between Warburg effect and
induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A; 101: 81327. 2004.
Ju JA, Godet I, Ye IC, Byun J, Jayatilaka H, Lee SJ, Xiang L, Samanta D, Lee
MH, Wu PH, Wirtz D, Semenza GL, Gilkes DM. Hypoxia Selectively Enhances
Integrin α(5)β(1) Receptor Expression in Breast Cancer to Promote Metastasis.
Mol Cancer Res; 15: 723-34. 2017.
Ryu MH, Park HM, Chung J, Lee CH, Park HR. Hypoxia-inducible factor-1alpha
mediates oral squamous cell carcinoma invasion via upregulation of alpha5
integrin and fibronectin. Biochem Biophys Res Commun; 393: 11-5. 2010.
Wu X, Cai J, Zuo Z, Li J. Collagen facilitates the colorectal cancer stemness and
metastasis through an integrin/PI3K/AKT/Snail signaling pathway. Biomed
Pharmacother; 114: 108708. 2019.
Chen WC, Chang YS, Hsu HP, Yen MC, Huang HL, Cho CY, Wang CY, Weng
TY, Lai PT, Chen CS, Lin YJ, Lai MD. Therapeutics targeting CD90-integrinAMPK-CD133 signal axis in liver cancer. Oncotarget; 6: 42923-37. 2015.
Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal
peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol; 22:
7692-707. 2016.
de Cuba EM, Kwakman R, van Egmond M, Bosch LJ, Bonjer HJ, Meijer GA, te
Velde EA. Understanding molecular mechanisms in peritoneal dissemination of
colorectal cancer : future possibilities for personalised treatment by use of
biomarkers. Virchows Arch; 461: 231-43. 2012.
Pretzsch E, Bösch F, Neumann J, Ganschow P, Bazhin A, Guba M, Werner J,
Angele M. Mechanisms of Metastasis in Colorectal Cancer and Metastatic
67
Organotropism: Hematogenous versus Peritoneal Spread. J Oncol; 2019:
7407190. 2019.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
Nakashio T, Narita T, Akiyama S, Kasai Y, Kondo K, Ito K, Takagi H, Kannagi R.
Adhesion molecules and TGF-beta1 are involved in the peritoneal dissemination
of NUGC-4 human gastric cancer cells. Int J Cancer; 70: 612-8. 1997.
Strobel T, Cannistra SA. Beta1-integrins partly mediate binding of ovarian cancer
cells to peritoneal mesothelium in vitro. Gynecol Oncol; 73: 362-7. 1999.
Hosono J, Narita T, Kimura N, Sato M, Nakashio T, Kasai Y, Nonami T, Nakao A,
Takagi H, Kannagi R. Involvement of adhesion molecules in metastasis of
SW1990, human pancreatic cancer cells. J Surg Oncol; 67: 77-84. 1998.
Oosterling SJ, van der Bij GJ, Bögels M, ten Raa S, Post JA, Meijer GA, Beelen
RH, van Egmond M. Anti-beta1 integrin antibody reduces surgery-induced
adhesion of colon carcinoma cells to traumatized peritoneal surfaces. Ann Surg;
247: 85-94. 2008.
Nagata H, Ishihara S, Kishikawa J, Sonoda H, Murono K, Emoto S, Kaneko M,
Sasaki K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Hata K, Kawai K,
Nozawa H. CD133 expression predicts post-operative recurrence in patients with
colon cancer with peritoneal metastasis. Int J Oncol; 52: 721-32. 2018.
Hongo K, Kazama S, Sunami E, Tsuno NH, Takahashi K, Nagawa H, Kitayama
J. Immunohistochemical detection of CD133 is associated with tumor regression
grade after chemoradiotherapy in rectal cancer. Med Oncol; 29: 2849-57. 2012.
Harada Y, Kazama S, Morikawa T, Murono K, Yasuda K, Otani K, Nishikawa T,
Tanaka T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Yamaguchi H, Ishihara S,
Watanabe T. Leucine-rich repeat-containing G protein-coupled receptor 5 and
CD133 expression is associated with tumor progression and resistance to
preoperative chemoradiotherapy in low rectal cancer. Oncol Lett; 14: 7791-98.
2017.
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM.
Epidemiology and management of liver metastases from colorectal cancer. Ann
Surg; 244: 254-9. 2006.
Engstrand J, Nilsson H, Strömberg C, Jonas E, Freedman J. Colorectal cancer
liver metastases - a population-based study on incidence, management and
survival. BMC Cancer; 18: 78. 2018.
Ravn S, Heide-Jørgensen U, Christiansen CF, Verwaal VJ, Hagemann-Madsen
RH, Iversen LH. Overall risk and risk factors for metachronous peritoneal
metastasis after colorectal cancer surgery: a nationwide cohort study. BJS Open;
68
85.
86.
87.
88.
89.
4: 284-92. 2020.
Zhang H, Yang N, Sun B, Jiang Y, Hou C, Ji C, Zhang Y, Liu Y, Zuo P. CD133
positive cells isolated from A549 cell line exhibited high liver metastatic potential.
Neoplasma; 61: 153-60. 2014.
Jing F, Kim HJ, Kim CH, Kim YJ, Lee JH, Kim HR. Colon cancer stem cell
markers CD44 and CD133 in patients with colorectal cancer and synchronous
hepatic metastases. Int J Oncol; 46: 1582-8. 2015.
Huang X, Sheng Y, Guan M. Co-expression of stem cell genes CD133 and CD44
in colorectal cancers with early liver metastasis. Surg Oncol; 21: 103-7. 2012.
Mitsui H, Shibata K, Suzuki S, Umezu T, Mizuno M, Kajiyama H, Kikkawa F.
Functional interaction between peritoneal mesothelial cells and stem cells of
ovarian yolk sac tumor (SC-OYST) in peritoneal dissemination. Gynecol Oncol;
124: 303-10. 2012.
Neumann J, Löhrs L, Albertsmeier M, Reu S, Guba M, Werner J, Kirchner T,
Angele M. Cancer Stem Cell Markers Are Associated With Distant
Hematogenous Liver Metastases But Not With Peritoneal Carcinomatosis in
Colorectal Cancer. Cancer Invest; 33: 354-60. 2015.
69
...
論文の公開元へ
